Carcinoma of unknown primary
Information
- Disease name
- Carcinoma of unknown primary
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03391973 | Active, not recruiting | Phase 2 | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | August 24, 2018 | December 30, 2024 |
| NCT02721732 | Active, not recruiting | Phase 2 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | August 15, 2016 | December 31, 2025 |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT00003943 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | September 1998 | February 2003 |
| NCT00004005 | Completed | Phase 2 | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin | September 1998 | October 2005 |
| NCT00004922 | Completed | Phase 2 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | June 1999 | June 2002 |
| NCT00006361 | Completed | Phase 2 | SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck | December 2000 | |
| NCT00014456 | Completed | Phase 1 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors | March 2000 | October 2005 |
| NCT00047125 | Completed | Phase 3 | Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor | July 2002 | |
| NCT00066781 | Completed | Phase 2 | Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary | February 2004 | March 2009 |
| NCT00002507 | Completed | Phase 3 | Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer | November 1992 | October 2002 |
| NCT00003582 | Completed | Phase 1/Phase 2 | Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer | May 1988 | December 1996 |
| NCT00003657 | Completed | Phase 2 | High-dose ICE With Amifostine | July 1998 | June 2002 |
| NCT00357630 | Completed | Phase 2 | Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary | June 2006 | |
| NCT00388024 | Completed | PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy | February 2006 | January 2015 | |
| NCT00873119 | Completed | Phase 2 | Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | February 2009 | December 2012 |
| NCT04189107 | Completed | Phase 3 | Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS | August 18, 2020 | November 9, 2022 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT05144698 | Recruiting | Phase 1/Phase 2 | RAPA-201 Therapy of Solid Tumors | August 1, 2021 | December 31, 2024 |
| NCT03010150 | Recruiting | Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer | December 29, 2016 | December 31, 2028 | |
| NCT03740503 | Recruiting | Genomic Investigation of Unusual Responders | November 1, 2013 | November 2024 | |
| NCT05887492 | Recruiting | Phase 1/Phase 2 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | June 12, 2023 | June 2025 |
| NCT04475640 | Recruiting | N/A | Cancer Genetic Testing in Ethnic Populations | December 13, 2019 | October 15, 2024 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT05461430 | Recruiting | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | July 15, 2022 | July 2026 | |
| NCT00148135 | Terminated | Phase 2 | Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site | May 2001 | October 2007 |
| NCT00112619 | Terminated | Phase 1 | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors | August 2005 | |
| NCT00022178 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin | December 1998 | |
| NCT00003558 | Unknown status | Phase 3 | Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin | August 1998 | |
| NCT02764216 | Unknown status | Phase 2 | Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary | January 2010 | December 2020 |
| NCT02590055 | Unknown status | Phase 2 | Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary | October 2015 | September 2019 |
| NCT00119314 | Withdrawn | Phase 2 | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin | July 2004 | July 2005 |